reports
- Ahmed Ben Salem
LHN HOLCIM AG
GET GETLINK SE
VIE VEOLIA ENVIRONNEMENT SA
SGO COMPAGNIE DE SAINT-GOBAIN SA
ENGI ENGIE SA.
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
PUM PUMA SE
ALV ALLIANZ SE
TEP TELEPERFORMANCE SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
GRF GRIFOLS S.A. CLASS A
BAS BASF SE
BCP BANCO COMERCIAL PORTUGUES S.A.
UCB UCB S.A.
WPP WPP PLC
ANA ACCIONA SA
ACKB ACKERMANS & VAN HAAREN NV
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
KGX KION GROUP AG
IBE IBERDROLA SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
SAN BANCO SANTANDER S.A.
GRF.P GRIFOLS S.A. PREF CLASS B
DHER DELIVERY HERO SE
BIM BIOMERIEUX SA
STLA STELLANTIS N.V.
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
STMN STRAUMANN HOLDING AG
H2O HIDROELECTRICA S.A.
- Ahmed Ben Salem
LHN HOLCIM AG
GET GETLINK SE
VIE VEOLIA ENVIRONNEMENT SA
SGO COMPAGNIE DE SAINT-GOBAIN SA
ENGI ENGIE SA.
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
PUM PUMA SE
ALV ALLIANZ SE
TEP TELEPERFORMANCE SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
GRF GRIFOLS S.A. CLASS A
BAS BASF SE
BCP BANCO COMERCIAL PORTUGUES S.A.
UCB UCB S.A.
WPP WPP PLC
ANA ACCIONA SA
ACKB ACKERMANS & VAN HAAREN NV
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
KGX KION GROUP AG
IBE IBERDROLA SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
SAN BANCO SANTANDER S.A.
GRF.P GRIFOLS S.A. PREF CLASS B
DHER DELIVERY HERO SE
BIM BIOMERIEUX SA
STLA STELLANTIS N.V.
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
STMN STRAUMANN HOLDING AG
H2O HIDROELECTRICA S.A.
- Martial Descoutures
- Martial Descoutures
- Chaima Ferrandon
- Sven Edelfelt
GET GETLINK SE
VIE VEOLIA ENVIRONNEMENT SA
RR. ROLLS-ROYCE HOLDINGS PLC
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
BVI BUREAU VERITAS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
PUM PUMA SE
SK SEB SA
FGR EIFFAGE SA
EBS ERSTE GROUP BANK AG
EN BOUYGUES SA
LSEG LONDON STOCK EXCHANGE GROUP PLC
EOAN E.ON SE
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
PZU POWSZECHNY ZAKLAD UBEZPIECZEN SPOLKA AKCYJNA
HEI HEIDELBERGCEMENT AG
UCB UCB S.A.
DTE DEUTSCHE TELEKOM AG
WPP WPP PLC
EDW EDP RENOVAVEIS SA
KGX KION GROUP AG
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
PRY PRYSMIAN S.P.A.
IBE IBERDROLA SA
PIRC PIRELLI & C. S.P.A.
ARGX ARGEN-X SE
HAG HENSOLDT AG
STLA STELLANTIS N.V.
CTPNV CTP NV
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
FER FERROVIAL SA
SYENS SYENSQO
- Chaima Ferrandon
- Sven Edelfelt
GET GETLINK SE
VIE VEOLIA ENVIRONNEMENT SA
RR. ROLLS-ROYCE HOLDINGS PLC
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
BVI BUREAU VERITAS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
PUM PUMA SE
SK SEB SA
FGR EIFFAGE SA
EN BOUYGUES SA
LSEG LONDON STOCK EXCHANGE GROUP PLC
EOAN E.ON SE
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
PZU POWSZECHNY ZAKLAD UBEZPIECZEN SPOLKA AKCYJNA
HEI HEIDELBERGCEMENT AG
UCB UCB S.A.
DTE DEUTSCHE TELEKOM AG
WPP WPP PLC
EDW EDP RENOVAVEIS SA
KGX KION GROUP AG
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
PRY PRYSMIAN S.P.A.
IBE IBERDROLA SA
PIRC PIRELLI & C. S.P.A.
ARGX ARGEN-X SE
HAG HENSOLDT AG
STLA STELLANTIS N.V.
CTPNV CTP NV
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
FER FERROVIAL SA
SYENS SYENSQO
- Martial Descoutures
- Martial Descoutures
- Martial Descoutures
- ING Helpdesk
Benelux Morning Notes
Aalberts: In-line FY25, but low quality / AMG: 4Q25 beat by 7%; in-line 2026 guidance / Bekaert: In-line 2025, cautious outlook for 2026 to result in c.8% consensus cut / CMB.TECH: A small bit beat but not the full story / Corbion: Dividend sweetener / CTP: Q4 results lighter due to some delays; stronger 2026 outlook / DEME: Strong FY25 numbers and FY26 outlook / Elia Group: Preview FY25 results / SBM Offshore: Another step-up in shareholder return / Syensqo: Substantial miss in 4Q25; FY26 outlo...
- Martial Descoutures
- Mathijs Geerts Danau
Sequana Medical Reports 5 centres with alfapump implants since launch
Sequana announces progress in the commercial uptake of the alfapump. We estimate at least 8 implants across 5 hospitals since launch in 2H25. The soft-launch target was 70 implants by end of 1Q26. However, we view this target as challenging to reach. We therefore await FY25 results for greater visibility on definitive sales figures and launch metrics. We reiterate our BUY and € 2.7 TP.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
BE Semiconductor Industries N.V: 2 directors
Two Directors at BE Semiconductor Industries N.V sold 21,875 shares at between 180.780EUR and 183.780EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...
- Jacob Mekhael
argenx FY25 results come with positive phase 3 ocular MG readout
argenx reported $4.2b (CSS: $ 4.13b) in FY25 global product net sales and operating income of $ 1.1b marking 2025 argenx first year of operating profitability. A major update is the positive ocular MG readout that will expand the MG patient population with 7K patients. This year we look forward to the myositis readout in 3Q26 and the empasiprubart readout in MMN in 4Q26. We reiterate our € 900 TP and BUY rating.
- Jacob Mekhael
UCB FY25 results show another Bimzelx-driven CSS beat
UCB reported another CSS beat with FY25 revenue of € 7,741m coming in 1.7% above expectations driven by stellar performance from Bimzelx, which generated € 2,227m in sales, 5.8% above expectations. We note that adj. EBITDA and net profit also came in above CSS despite increased investments in sales and marketing. With head to head data for Bimzelx vs. Skyrizi in PsA now expected in 1H26, we continue to view UCB as an attractive name to own, and reiterate our € 284 TP and BUY rating.
argenx Reports Full Year 2025 Financial Results and Provides Fourth Qu...
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET ...
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Tr...
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information February 26, 2026, 6:30 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company co...
- ING Helpdesk
Benelux Morning Notes
Ageas: Upgrading net op. result FY26 target to >€1.5bn from €1.35bn in FY25 as M&A starts contributing / CFE: Strong 2H, flips to net cash and outlook better / Deceuninck: FY25 results in line with expectations, Türkiye a tad better / GBL: Exits Umicore fully / Vopak: Five-year SBB programme announced / Wolters Kluwer: 2025 roughly in line, good 2026 outlook
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.